NCT00096941View on ClinicalTrials.gov

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

PHASE2CompletedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Solid Cancers

Interventions

DRUG

Pertuzumab

Pertuzumab was supplied as a single-use liquid formulation.

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY